nach oben

Der Nervenarzt

Erschienen in:

06.09.2023 | Psychopharmakotherapie | CME

Gewichtszunahme unter Therapie mit Psychopharmaka

Hintergründe und Management

verfasst von: J. Eder, M. S. Simon, Dr. med. C. Glocker, R. Musil

Erschienen in: Der Nervenarzt | Ausgabe 9/2023

zum CME-Kurs Einloggen, um Zugang zu erhalten

Zusammenfassung

Psychopharmakaassoziierte Gewichtszunahme (PAGZ) ist eine bekannte, häufige und für die Prognose der Patienten relevante Nebenwirkung. Die einzelnen Medikamente haben unterschiedlich hohe Risiken für das Auftreten der PAGZ, gleichzeitig gibt es individuelle Risikofaktoren seitens der Patienten wie Alter, Geschlecht, metabolische und genetische Faktoren. Da die metabolischen Veränderungen im Rahmen einer PAGZ langfristig eine erhöhte Mortalität zur Folge haben, gilt es, durch eine entsprechende Prävention vorzubeugen und im Fall einer bereits eingetretenen PAGZ gezielt zu intervenieren. Ein entsprechendes Monitoring ist deshalb unerlässlich. Dieser Artikel gibt einen Überblick über zugrunde liegende Mechanismen, Risikokonstellationen und mögliche Gegenmaßnahmen.

Walker ER, McGee RE, Druss BG (2015) Mortality in mental disorders and global disease burden implications: a systematic review and meta-analysis. JAMA Psychiatry 72(4):334–341 PubMedPubMedCentral

Manu P, Dima L, Shulman M, Vancampfort D, De Hert M, Correll CU (2015) Weight gain and obesity in schizophrenia: epidemiology, pathobiology, and management. Acta Psychiatr Scand 132(2):97–108 PubMed

Tiihonen J, Lönnqvist J, Wahlbeck K, Klaukka T, Niskanen L, Tanskanen A et al (2009) 11-year follow-up of mortality in patients with schizophrenia: a population-based cohort study (FIN11 study). Lancet 374(9690):620–627 PubMed

Verhaeghe N, De Maeseneer J, Maes L, Van Heeringen C, Annemans L (2011) Effectiveness and cost-effectiveness of lifestyle interventions on physical activity and eating habits in persons with severe mental disorders: a systematic review. Int J Behav Nutr Phys Act 8(1):28 PubMedPubMedCentral

Vandenberghe F, Gholam-Rezaee M, Saigí-Morgui N, Delacrétaz A, Choong E, Solida-Tozzi A et al (2015) Importance of early weight changes to predict long-term weight gain during psychotropic drug treatment. J Clin Psychiatry 76(11):e1417–e1423 PubMed

DGPPN e. V. für die Leitliniengruppe (2019) S3-Leitlinie Schizophrenie. https://www.awmf.org/leitlinien/detail/ll/038-009.html. Zugegriffen: 24.04.2023

Barton B, Simon M, Glocker C, Musil R (2020) Was tun, wenn das Körpergewicht unter Psychopharmaka ansteigt? InFo Neurologie 22(12):30–39

Barton BB, Segger F, Fischer K, Obermeier M, Musil R (2020) Update on weight-gain caused by antipsychotics: a systematic review and meta-analysis. Expert Opin Drug Saf 19(3):295–314 PubMed

Musil R, Obermeier M, Russ P, Hamerle M (2015) Weight gain and antipsychotics: a drug safety review. Expert Opin Drug Saf 14(1):73–96 PubMed

10.

Bak M, Fransen A, Janssen J, van Os J, Drukker M (2014) Almost all antipsychotics result in weight gain: a meta-analysis. PLoS ONE 9(4):e94112 PubMedPubMedCentral

11.

Pillinger T, McCutcheon RA, Vano L, Mizuno Y, Arumuham A, Hindley G et al (2020) Comparative effects of 18 antipsychotics on metabolic function in patients with schizophrenia, predictors of metabolic dysregulation, and association with psychopathology: a systematic review and network meta-analysis. Lancet Psychiatry 7(1):64–77 PubMedPubMedCentral

12.

Rognoni C, Bertolani A, Jommi C (2021) Second-generation antipsychotic drugs for patients with schizophrenia: systematic literature review and meta-analysis of metabolic and cardiovascular side effects. Clin Drug Investig 41(4):303–319 PubMedPubMedCentral

13.

Dent R, Blackmore A, Peterson J, Habib R, Kay GP, Gervais A et al (2012) Changes in body weight and psychotropic drugs: a systematic synthesis of the literature. PLoS ONE 7(6):e36889 PubMedPubMedCentral

14.

Gill H, Gill B, El-Halabi S, Chen-Li D, Lipsitz O, Rosenblat JD et al (2020) Antidepressant medications and weight change: a narrative review. Obesity 28(11):2064–2072 PubMed

15.

Huhn M, Nikolakopoulou A, Schneider-Thoma J, Krause M, Samara M, Peter N et al (2019) Comparative efficacy and tolerability of 32 oral antipsychotics for the acute treatment of adults with multi-episode schizophrenia: a systematic review and network meta-analysis. Lancet 394(10202):939–951 PubMedPubMedCentral

16.

Wharton S, Raiber L, Serodio KJ, Lee J, Christensen RAG (2018) Medications that cause weight gain and alternatives in Canada: a narrative review. DMSO 11:427–438

17.

Grootens KP, Meijer A, Hartong EG, Doornbos B, Bakker PR, Al Hadithy A et al (2018) Weight changes associated with antiepileptic mood stabilizers in the treatment of bipolar disorder. Eur J Clin Pharmacol 74(11):1485–1489 PubMed

18.

Grohmann R, Engel RR, Rüther E, Hippius H (2004) The AMSP drug safety program: methods and global results. Pharmacopsychiatry 37(Suppl 1):S4–11 PubMed

19.

Schneider M, Pauwels P, Toto S, Bleich S, Grohmann R, Heinze M et al (2020) Severe weight gain as an adverse drug reaction of psychotropics: data from the AMSP project between 2001 and 2016. Eur Neuropsychopharmacol 36:60–71 PubMed

20.

Sabé M, Pallis K, Solmi M, Crippa A, Sentissi O, Kaiser S (2023) Comparative effects of 11 antipsychotics on weight gain and metabolic function in patients with acute schizophrenia: a dose-response meta-analysis. J Clin Psychiatry 84(2):22r14490. https://doi.org/10.4088/JCP.22r14490 CrossRef

21.

Ishikawa S, Yamamura R, Hashimoto N, Okubo R, Sawagashira R, Ito YM et al (2022) The type rather than the daily dose or number of antipsychotics affects the incidence of hyperglycemic progression. Prog Neuropsychopharmacol Biol Psychiatry 113:110453 PubMed

22.

Teasdale SB, Ward PB, Samaras K, Firth J, Stubbs B, Tripodi E et al (2019) Dietary intake of people with severe mental illness: systematic review and meta-analysis. Br J Psychiatry 214(5):251–259 PubMed

23.

Vancampfort D, Firth J, Schuch FB, Rosenbaum S, Mugisha J, Hallgren M et al (2017) Sedentary behavior and physical activity levels in people with schizophrenia, bipolar disorder and major depressive disorder: a global systematic review and meta-analysis. World Psychiatry 16(3):308–315 PubMedPubMedCentral

24.

Mutwalli H, Keeler JL, Bektas S, Dhopatkar N, Treasure J, Himmerich H (2023) Eating cognitions, emotions and behaviour under treatment with second generation antipsychotics: a systematic review and meta-analysis. J Psychiatr Res 160:137–162 PubMed

25.

Smith E, Singh R, Lee J, Colucci L, Graff-Guerrero A, Remington G et al (2021) Adiposity in schizophrenia: a systematic review and meta-analysis. Acta Psychiatr Scand 144(6):524–536 PubMed

26.

Kucera J, Horska K, Hruska P, Kuruczova D, Micale V, Ruda-Kucerova J et al (2021) Interacting effects of the MAM model of schizophrenia and antipsychotic treatment: untargeted proteomics approach in adipose tissue. Prog Neuropsychopharmacol Biol Psychiatry 108:110165 PubMed

27.

Grajales D, Ferreira V, Valverde ÁM (2019) Second-generation antipsychotics and dysregulation of glucose metabolism: beyond weight gain. Cells 8(11):1336. https://doi.org/10.3390/cells8111336 CrossRefPubMedPubMedCentral

28.

Kishi T, Elmquist JK (2005) Body weight is regulated by the brain: a link between feeding and emotion. Mol Psychiatry 10(2):132–146 PubMed

29.

Zhang JP, Lencz T, Zhang RX, Nitta M, Maayan L, John M et al (2016) Pharmacogenetic associations of antipsychotic drug-related weight gain: a systematic review and meta-analysis. Schizophr Bull 42(6):1418–1437 PubMedPubMedCentral

30.

Muntané G, Vázquez-Bourgon J, Sada E, Martorell L, Papiol S, Bosch E et al (2023) Polygenic risk scores enhance prediction of body mass index increase in individuals with a first episode of psychosis. Eur Psychiatry 66(1):1–28

31.

Gebhardt S, Haberhausen M, Heinzel-Gutenbrunner M, Gebhardt N, Remschmidt H, Krieg JC et al (2009) Antipsychotic-induced body weight gain: predictors and a systematic categorization of the long-term weight course. J Psychiatr Res 43(6):620–626 PubMed

32.

Lane HY, Liu YC, Huang CL, Chang YC, Wu PL, Lu CT et al (2006) Risperidone-related weight gain: genetic and nongenetic predictors. J Clin Psychopharmacol 26(2):128–134 PubMed

33.

Basson BR, Kinon BJ, Taylor CC, Szymanski KA, Gilmore JA, Tollefson GD (2001) Factors influencing acute weight change in patients with schizophrenia treated with olanzapine, haloperidol, or risperidone. J Clin Psychiatry 62(4):231–238 PubMed

34.

Simon MS, Barton B, Zagler A, Engl K, Rihs L, Glocker C et al (2023) Lifestyle behaviors, metabolic disturbances, and weight gain in psychiatric inpatients treated with weight gain-associated medication. Eur Arch Psychiatry Clin Neurosci 273(4):839–851. https://doi.org/10.1007/s00406-022-01442-4 CrossRefPubMed

35.

Brandl EJ, Frydrychowicz C, Tiwari AK, Lett TA, Kitzrow W, Büttner S et al (2012) Association study of polymorphisms in leptin and leptin receptor genes with antipsychotic-induced body weight gain. Prog Neuropsychopharmacol Biol Psychiatry 38(2):134–141 PubMed

36.

Hinney A, Körner A, Fischer-Posovszky P (2022) The promise of new anti-obesity therapies arising from knowledge of genetic obesity traits. Nat Rev Endocrinol 18(10):623–637 PubMedPubMedCentral

37.

Dobrodeeva VS, Shnayder NA, Novitsky MA, Asadullin AR, Vaiman EE, Petrova MM et al (2022) Association of a single-nucleotide variant rs11100494 of the NPY5R gene with antipsychotic-induced metabolic disorders. Pharmaceutics 14(2):222 PubMedPubMedCentral

38.

De Hert M, Dekker JM, Wood D, Kahl KG, Holt RIG, Möller HJ (2009) Cardiovascular disease and diabetes in people with severe mental illness position statement from the European PsychiatricAssociation (EPA), supported by the European Association for the Study of Diabetes (EASD) and the European Society of Cardiology (ESC). Eur Psychiatry 24(6):412–424 PubMed

39.

DGBS e. V., DGPPN e. V. (2019) S3-Leitlinie zur Diagnostik und Therapie Bipolarer Störungen Langversion

40.

DGPPN, BÄK, KBV, AWMF (Hrsg) für die Leitliniengruppe Unipolare Depression (2015) S3-Leitlinie/Nationale Versorgungs-Leitlinie Unipolare Depression – Langfassung. https://www.depression.versorgungsleitlinien.de

41.

Bonfioli E, Berti L, Goss C, Muraro F, Burti L (2012) Health promotion lifestyle interventions for weight management in psychosis: a systematic review and meta-analysis of randomised controlled trials. BMC Psychiatry 12:78. https://doi.org/10.1186/1471-244X-12-78 CrossRefPubMedPubMedCentral

42.

Bartels S, Desilets R (2012) Health promotion programs for people with serious mental illness. SAMHSA-HRSA Center for Integrated Health Solutions, Washington

43.

Walburg FS, van Meijel B, Hoekstra T, Kol J, Pape LM, de Joode JW et al (2023) Effectiveness of a lifestyle intervention for people with a severe mental illness in Dutch outpatient mental health care: a randomized clinical trial. JAMA Psychiatry. https://doi.org/10.1001/jamapsychiatry.2023.1566 CrossRefPubMedPubMedCentral

44.

Stubbs B, Vancampfort D, Hallgren M, Firth J, Veronese N, Solmi M et al (2018) EPA guidance on physical activity as a treatment for severe mental illness: a meta-review of the evidence and position statement from the European psychiatric association (EPA), supported by the international organization of physical therapists in mental. Eur Psychiatry 54:124–144 PubMed

45.

World Health Organization (2021) Obesity and overweight. https://www.who.int/news-room/fact-sheets/detail/obesity-and-overweight. Zugegriffen: 31.01.2022

46.

Lee K, Abraham S, Cleaver R (2022) A systematic review of licensed weight-loss medications in treating antipsychotic-induced weight gain and obesity in schizophrenia and psychosis. Gen Hosp Psychiatry 78:58–67 PubMed

47.

Hakami AY, Felemban R, Ahmad RG, Al-Samadani AH, Salamatullah HK, Baljoon JM et al (2022) The association between antipsychotics and weight gain and the potential role of metformin concomitant use: a retrospective cohort study. Front Psychiatry 13:914165 PubMedPubMedCentral

48.

Fitzgerald I, O’Connell J, Keating D, Hynes C, McWilliams S, Crowley EK (2022) Metformin in the management of antipsychotic-induced weight gain in adults with psychosis: development of the first evidence-based guideline using GRADE methodology. Evid Based Ment Health 25(1):15–22 PubMed

49.

Zheng W, Zhang QE, Cai DB, Yang XH, Ungvari GS, Ng CH et al (2019) Combination of metformin and lifestyle intervention for antipsychotic-related weight gain: a meta-analysis of randomized controlled trials. Pharmacopsychiatry 52(1):24–31 PubMed

50.

McIntyre RS, Paron E, Burrows M, Blavignac J, Gould E, Camacho F et al (2021) Psychiatric safety and weight loss efficacy of naltrexone/bupropion as add-on to antidepressant therapy in patients with obesity or overweight. J Affect Disord 289:167–176 PubMed

51.

Lyu X, Du J, Zhan G, Wu Y, Su H, Zhu Y et al (2018) Naltrexone and bupropion combination treatment for smoking cessation and weight loss in patients with schizophrenia. Front Pharmacol 9:181 PubMedPubMedCentral

52.

Shi Q, Wang Y, Hao Q, Vandvik PO, Guyatt G, Li J et al (2022) Pharmacotherapy for adults with overweight and obesity: a systematic review and network meta-analysis of randomised controlled trials. Lancet 399(10321):259–269 PubMed

53.

UK NCGC (2014) Obesity: identification, assessment and management of overweight and obesity in children, young people and adults

54.

UK NCGC (2023) Semaglutide for managing overweight and obesity

55.

Siskind D, Hahn M, Correll CU, Fink-Jensen A, Russell AW, Bak N et al (2019) Glucagon-like peptide‑1 receptor agonists for antipsychotic-associated cardio-metabolic risk factors: a systematic review and individual participant data meta-analysis. Diabetes Obes Metab 21(2):293–302 PubMed

56.

Paik J (2021) Olanzapine/Samidorphan: first approval. Drugs 81(12):1431–1436 PubMed

57.

Jawad MY, Alnefeesi Y, Lui LMW, Ceban F, Chen-Li DCJ, Teopiz K et al (2022) Olanzapine and samidorphan combination treatment: a systematic review. J Affect Disord 301:99–106 PubMed

58.

Pressanto C, Scholtz S, Ali N (2023) Obesity and bariatric surgery in adults living with severe mental illness: perceptions and clinical challenges. BJPsych Bull 47(3):165–171 PubMedPubMedCentral

Titel: Gewichtszunahme unter Therapie mit Psychopharmaka
Hintergründe und Management
verfasst von: J. Eder
M. S. Simon
Dr. med. C. Glocker
R. Musil
Publikationsdatum: 06.09.2023
Verlag: Springer Medizin
Schlagwörter: Psychopharmakotherapie
Antipsychotika
Antipsychotika
Antidepressiva
Antidepressiva
Olanzapin
Erschienen in: Der Nervenarzt / Ausgabe 9/2023
Print ISSN: 0028-2804
Elektronische ISSN: 1433-0407
DOI: https://doi.org/10.1007/s00115-023-01534-z

Impuls - Die Nachhaltigkeitsinitiative von Springer Medizin

Springer Medizin

Zusammenfassung

Bitte loggen Sie sich ein, um Zugang zu diesem Inhalt zu erhalten

Weitere Artikel der Ausgabe 9/2023

Mitteilungen der DGPPN 9/2023

Was rechtlich bei der Verordnung medizinischen Cannabis zu beachten ist

Psychopharmakotherapie in der Schwangerschaft und Stillzeit – Teil II: Schwerpunkt Stillzeit

Psychische Erkrankungen in der Zeit um die Geburt: eine interdisziplinäre und sektorenübergreifende Herausforderung

Expositionstherapie bei Panikstörung und Agoraphobie im Kontext bestehender antidepressiver Medikation

Traumatische Geburt und traumasensible Geburtsbegleitung